The program began July 1, 2026, and is currently scheduled to continue through December 31, 2027
One difference noted in clinical trials: oral semaglutide patients reported excessive belching more frequently (14% vs
GLP-1 medications are a legitimate tool particularly for patients who don't meet surgical criteria, want to reduce surgical risk beforehand, or to prepare for a bariatric procedure
doi: 10.1111/exd.12081 187 HoganAETobinAMAhernTCorriganMAGaoatsweGJacksonRet al
They review your medical history, current medications, and goals
Some analyses show 12-58% of products contain contamination, 30% have incorrect amino acid sequences, 65% exceed endotoxin safety thresholds, and 20% are mislabeled entirely